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An 80-year-old Japanese womanwith wet cough and dyspnea was diagnosed with pneumonia at a clinic.
Antibiotics did not improve her symptoms; therefore, she was referred to our hospital one month after
symptom onset. Chest radiograph ﬁndings revealed complete collapse of the left lung. Bronchoscopy
showed white mucus plug in the left main bronchus, which could not be removed. She was initially
treated with bromhexine. Subsequently, culture results of the mucus plug specimen obtained during
bronchoscopy yielded Schizophyllum commune. After three weeks, improvement of the collapsed lung
was observed on chest radiograph.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Schizophyllum commune is a common species of fungus (mush-
room) that colonizes diverse trees and rotting wood worldwide.
Inhalation exposure to this environmental fungus is possible during
usual activities of daily living. In 1994, Kamei reported the ﬁrst case
of allergic bronchopulmonary mycosis (ABPM) caused by
S. commune infection [1]. Recently, an increasing number of cases of
ABPM and mucoid impaction of the bronchi (MIB) secondary to
S. commune infection has been reported, most of which were from
Japan [2]. Some reports have indicated good response to treatment
with antifungal drugs and/or corticosteroids; however, many pa-
tients develop resistance to such therapy [3e6]. Therefore, there
remain many unclear aspects on the treatment, as well the risk
factors and pathogenesis, of ABPM and MIB caused by S. commune.
Herein, we report the ﬁrst case of a favorable clinical effect of an
expectorant agent against ABPM. This report may contribute to the
improvement of treatment of ABPM caused by S. commune.ogy, Shizuoka Cancer Center,
Shizuoka, 411-8777, Japan.
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An 80-year-old Japanese female, with a 48-pack years smoking
history, presented to a clinic complaining of wet cough and
breathing difﬁculty. She had a past history of tuberculosis, but there
was no history or symptoms suggestive of asthma. Chest radio-
graph revealed left lower lobe collapse (Fig.1). Shewas hospitalized
after being diagnosed with pneumonia and treated with antibiotics
(ampicillin/sulbactam). However, the initial treatment was inef-
fective, and radiograph ﬁndings progressively worsened within
weeks. Therefore, she was transferred to our hospital for evaluation
and treatment at one month after symptom onset.
Upon examination, SpO2 was 89% at room air. Laboratory test
showed elevated eosinophil count at 651/mL. Additionally, chest
radiograph and computed tomography (CT) ﬁndings revealed
complete collapse of the left lung with hyperattenuated mucoid
(HAM) impaction (Fig. 2). Bronchoscopy showed a white, rubbery,
thick mucus plug in the left main bronchus, which could not be
removed by forceps or suction (Fig. 3). The ﬁndings on pathologic
examination were eosinophilic inﬁltration without Charcot-
Leyden crystals on Hematoxylin and Eosin stain and presence of
fungal mycelium on Grocott stain. Culture of the small pieces of the
mucus plug obtained during bronchoscopy yielded S. commune.
The patient was treated with an expectorant agent, bromhex-
ine 8 mg three times daily, after the bronchoscopy. Three weeksnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chest radiograph on the ﬁrst visit shows left lower lobe collapse.
Fig. 2. Chest computed tomography obtained upon admission shows complete
collapse of the left lung with hyperattenuated mucoid impaction.
Fig. 3. Bronchoscopy ﬁndings show white mucus plug in left main bronchus.
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collapsed left lung (Fig. 4A). Two months later, while she was
completely recuperating from wet cough and breathing difﬁculty,
SpO2 increased to 97% at room air and chest CT showed complete
recovery of the collapsed lung, but with central bronchiectasis
seen (Fig. 4B). Subsequently, she has returned to the clinic for
follow-up and has continued bromhexine treatment successfully
for more than 20 months. There were no adverse effects of
bromhexine.3. Discussion
Antifungal drugs and/or corticosteroids are frequently the ﬁrst
choice of treatment for ABPM. According to the previously reported
18 cases of ABPM and MIB secondary to S. commune in Japan
[1,3e16], patients were initially treated with antifungal drug
(n ¼ 6); systemic corticosteroid (n ¼ 1); combination of antifungal
drugs and systemic corticosteroids (n ¼ 4), with the addition of
inhaled corticosteroids (n ¼ 3); bronchoscopic drainage (n ¼ 1),
with the addition of inhaled corticosteroids (n ¼ 1); and combi-
nation of systemic and inhaled corticosteroids (n¼ 2). To the best of
our knowledge, this was the ﬁrst report of a favorable clinical effectof an expectorant agent alone in a patient with ABPM secondary to
S. commune infection.
The efﬁcacy of bromhexine is as follows: 1) promoting serous
secretion, 2) dissolving content of acid glycoprotein ﬁbers, and 3)
increasing the ciliary movement. In addition, it has been reported
that expectorant agents have anti-inﬂammatory effects [17,18].
Therefore, a possible explanation for the efﬁcacy of bromhexine in
this case was that the activated ciliary movement and reduced
inﬂammation facilitated removal of the dissolved mucoid impac-
tion. Expectorants have less adverse effects and cost less compared
with antifungal drugs and systemic corticosteroids. Based on these
results, expectorant agents may be considered a routine add-on
therapy to anti-fungal drugs and/or corticosteroids in patients
with ABPM secondary to S. commune in order to obtain better
response in the clinical setting.
There are no established diagnostic criteria for ABPM, especially
ABPM secondary to S. commune infection. However, the diagnostic
criteria for allergic bronchopulmonary aspergillosis (ABPA) are
generally accepted for ABPM by replacing Aspergillus fumigatus
with S. commune. In other words, the diagnostic criteria for ABPM
caused by S. commune should include the clinical, serologic, path-
ologic, microbiologic, and imaging ﬁndings that are used for the
diagnosis of ABPA. Katzenstein [19] and Bosken [20] have
mentioned the importance of mucus plugs. Speciﬁcally, detecting
an MIB that includes eosinophilic inﬁltration and fungus may be
designated as ABPM. The present case was characterized by
eosinophilic inﬁltration and the presence of S. commune in the
mucus plugs. Therefore, we diagnosed as ABPM caused by
S. commune. Goyal et al. revealed that HAM impaction on chest CT
was seen in ABPA [21], which is characterized to be denser than
skeletal muscle on CT. The possible reason for development of HAM
is the presence of calcium salts and metals (e.g., ions of iron and
manganese), hemorrhagic products, or desiccated mucus [21e24].
HAM has been reported to be encountered in 18.7e30% of patients
with ABPA [22,25,26], which is considered to be risk factor for
relapse [25]. Uruga et al. ﬁrst reported HAM caused by S. commune
in 2010 [6]. Central bronchiectasis is also known to be a feature of
ABPA on CT scan [27]. In addition, some reports revealed that
central bronchiectasis was seen in ABPM caused by S. commune
[2,5], through a mechanism mediated by T helper 2-type immune
responses and fungal proteases [28e30]. These CT scan ﬁndings
Fig. 4. (A) Chest radiograph three weeks after initiation of bromhexine treatment shows improvement of the collapsed lung. (B) Chest computed tomography two months after
initiation of bromhexine treatment shows central bronchiectasis and recovery of the collapsed lung.
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ﬁndings may lead to a diagnosis of ABPM caused by S. commune.
The Rosenberg and Patterson criteria [27], in which S. commune
replaces A. fumigatus, are most widely used for the diagnosis of
ABPM caused by S. commune. The primary criteria include 1)
episodic bronchial obstruction, 2) peripheral blood eosinophilia, 3)
immediate skin reactivity to S. commune antigen, 4) precipitating
antibodies against S. commune antigen, 5) elevated serum IgE
concentration, 6) history of pulmonary inﬁltrates, and 7) central
bronchiectasis. The secondary criteria include 1) S. commune in
sputum, 2) history of expectoration of brown plugs, and 3) arthus
reactivity to S. commune antigen. The presence of 6 primary
criteria was reported by Agarwel et al. to have a 100% sensitivity
and 100% speciﬁcity [31], whereas Ishiguro et al. reported a sensi-
tivity of 57.1% and speciﬁcity of 100%. This difference in sensitivity
of the criteria between the two studies may be accounted for by the
varying characteristics of patients with asthma in the study by
Ishiguro et al. In two other studies on patients with ABPM caused by
S. commune, Kamei et al. reported that only 30% had bronchial
asthma [32], whereas Glancy et al. reported that 74% had bronchial
asthma [33]. Therefore, the present criteria may have low sensi-
tivity for the diagnosis of ABPM caused by S. commune.
The diagnosis of ABPM was not made until culture of the mucus
plug obtained during bronchoscopy revealed S. commune. Initially,
our impressionwas a non-infectiousmucus plug. For this reason, all
diagnostic blood tests (serum IgE value, serum IgE antibody against
S. commune, and serum precipitating or IgG antibody against
S. commune), pulmonary function test, and treatment (antifungal
drugs and/or corticosteroids) for ABPM were not performed. This
was also the reason the patient was treatedwith bromhexine alone.
Surprisingly, bromhexine was able to exert a therapeutic effect in
this patient with ABPM secondary to S. commune infection by
allowing drainage of the rubbery thick mucus plug that could not
be removed by bronchoscopy.
In summary, we experienced a favorable clinical effect of an
expectorant agent against ABPM due to S. commune. Expectorant
agents, such as bromhexine, should be routinely used in the clinical
setting as an add-on therapy that can work synergistically with
antifungal drugs and/or corticosteroids in patients with ABPM
caused by S. commune.
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